Frontier
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 7, 2022; 28(5): 502-516
Published online Feb 7, 2022. doi: 10.3748/wjg.v28.i5.502
Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021
Jose Maria Huguet, Luis Ferrer-Barceló, Patrícia Suárez, Eva Sanchez, Jose David Prieto, Victor Garcia, Javier Sempere
Jose Maria Huguet, Luis Ferrer-Barceló, Patrícia Suárez, Eva Sanchez, Jose David Prieto, Victor Garcia, Javier Sempere, Department of Digestive Disease, General University Hospital of Valencia, Valencia 46014, Spain
Author contributions: Huguet JM, Ferrer-Barceló L, Suárez P, Sanchez E, Prieto JD, García V and Sempere J contributed to the conception of the study, collected materials and wrote the manuscript; All authors contributed to and approved the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jose Maria Huguet, MD, PhD, Assistant Professor, Department of Digestive Disease, General University Hospital of Valencia, Av Tres Cruces 2, Valencia 46014, Spain. josemahuguet@gmail.com
Received: March 18, 2021
Peer-review started: March 18, 2021
First decision: July 3, 2021
Revised: July 10, 2021
Accepted: January 17, 2022
Article in press: January 17, 2022
Published online: February 7, 2022
Core Tip

Core Tip: Patients with inflammatory bowel disease (IBD) are at greater risk of colorectal cancer over time. Therefore, a series of recommendations has been made for the follow-up of this population. We carried out a review in which we set out the main new developments in the detection, follow-up, and management of dysplasia in patients with IBD in recent years.